KIRYAT ATIDIM, BUILDING 7, TEL AVIV, L3
Market cap: $9.6M (2/09/2026)
Price: $1.56
Announces Third Quarter 2025 Financial Results and Provides Corporate Update—PSC Phase 3 Design Near Completion Following Positive FDA Feedback——Phase 2 SPRING Trial OLE Data Showing Favorable Safety and Consistent Improvements in Key Biomarkers in Patients Treated with Nebokitug for Up to 48 Weeks Presented at AASLD 2025——New Clinical Data Presented at AASLD 2025 Provides
Material disclosure
Chemomab Therapeutics Q2 2025 Financial Results and Corporate Update, Phase 3 Nebokitug Program Advances
Annual General Meeting July 1, 2025
Announces First Quarter 2025 Financial Results and Provides Corporate Update—Reported Positive 48-Week Data from SPRING Trial—Treatment in PSC Patients with Moderate/Advanced Disease Resulted in Continued Improvements across Key Biomarkers of Liver Injury, Inflammation and Fibrosis——Aligned with FDA on Pathway to Potential Regulatory Approval for the Treatment of PSC with a
Announces New Medical and Clinical Appointments
Annual and Transition Report of Foreign Private Issuers
Q1
FY 2022
Q3
Q2
FY 2021
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Post-Effective Amendment to Registration Statement
Correspondence